All Hong Kong stocks quotes are at least 15 minutes delayed.
02617
TRANSTHERA-B
HKD
70.600-2.750
(-3.75%)
1D
AI Analysis
High
74.000
Open
72.000
VWAP
71.33
Vol
740.50K
Mkt Cap
77.08B
Low
70.500
Amount
52.82M
EV/EBITDA(TTM)
--
Total Shares
396.90M
EV
3.66B
EV/OCF(TTM)
--
P/S(TTM)
--
TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
Show More
News
Money Flow
Over the past 66 trading days, overall net money flow is -41.17M, with retail investors contributing -8.64M and major investors adding -24.18M.
Net Buy $ Volume
Net Sell $ Volume

No data
Valuation Metrics
Forward PE

N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly

No data

No data
People Also Watch




